Incyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Incyte INCY announced that the FDA has approved its new drug, Zynyz (retifanlimab-dlwr), a PD-1 inhibitor, for treating a new ...

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

FDA lifts hold on Scynexis' ibrexafungerp Phase 3 fungal infection trial, but GSK plans to end study. Incyte's Zynyz gets FDA ...

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

The US Food and Drug Administration (FDA) has approved Incyte’s (Nasdaq: INCY) Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

This was the stock's second consecutive day of gains.

The US Court of Appeals for the Federal Circuit dismissed Incyte’s appeal of a Patent Trial & Appeal Board decision, holding that a ...